Now on

Orphan Drug Designation for the treatment of sickle cell disease also in USA

Sirolimus has been granted Orphan Drug Designation for the treatment of sickle cell disease also in USA

RP announcement - read more
Orphan Drug Designation to sirolimus in Sickle Cell Disease

Orphan Drug Designation to sirolimus in Sickle Cell Disease

RP announcement - read more
Orphan Drug Designation for the use of Teicoplanin in Cystic Fibrosis

The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners

RP announcement - read more
Rare Partners supports the Istituto Italiano di Tecnologia (IIT) for the development of an innovative artificial retina

Rare Partners supports the IIT for the development of an innovative artificial retina 

RP announcement - read more
A new Orphan Drug Designation to Sirolimus

A new Orphan Drug Designation to Sirolimus

RP announcement - read more